Medicare’s Decision to Cover the Alzheimer’s Drug Aduhelm: What Will It Mean for Patients and the Program?

Commonwealth Fund January 19, 2022
Gretchen Jacobson, Aimee Cicchiello

Toplines

At an annual per-patient price of $28,200, how would Medicare coverage of the controversial Alzheimer’s drug Aduhelm affect Medicare beneficiaries and program costs?

Medicare has proposed covering Aduhelm, a controversial and costly drug for treating mild Alzheimer’s disease, conditional on the drugmaker Biogen collecting additional safety and effectiveness data

On January 11, the Centers for Medicare and Medicaid Services (CMS) proposed that Medicare would cover Aduhelm, a drug for the treatment of mild Alzheimer’s disease, conditional on the drug manufacturer Biogen collecting more data on effectiveness and safety. Medicare will cover the drug only for beneficiaries enrolled in a clinical trial approved by CMS or supported by the National Institutes of Health (NIH). The price has been set at...

Today's Sponsors

Today's Sponsor